/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Privia Health Group, Inc. ( Privia Health , we , our , or the Company ) is a technology-driven, national physician-enablement company that collaborates with physician practices, health plans, and health systems to achieve the quadruple aim of better outcomes, lower costs, improved patient experience, and happier and more engaged providers. We seek to accomplish the quadruple aim by entering mar…
$20.64
+$0.15 (+0.73%)
EOD Sep 1, 2026
Operating margin is thin at 1.61%. Limited cushion if revenue slows or costs rise, not the profile of a wide-moat business.
Revenue grew 22.3%, still solid.
At 121x earnings, the current multiple leaves limited room for execution misses or growth deceleration.
121.4x earnings, 19.6x FCF. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$2.25B
▲ +22.3% YoY
Net Income (TTM)
$20M
▲ +59.3% YoY
Op. Margin
1.62%
▲ +0.6pp YoY
ROIC
2.57%
▲ +0.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$138M
▲ +49.5% YoY
Op. Cash Flow (TTM)
$138M
▲ +49.5% YoY
Net Debt
-$411M
Net Cash Position
Cash & Equiv.
$420M
5Y CAGR: +21.0%
5Y CAGR: +33.5%
Continue Research
SourceComputed from the 10-Q filed 7 May 2026, covering the period ending 31 Mar 2026, as reported to the SEC. Data last refreshed 24 Jun 2026. How this is calculated.
Price from market data, last close as of 1 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
At a P/E of 121.4 and a price-to-free-cash-flow of 19.6, Privia Health Group (PRVA) trades below a two-stage DCF intrinsic value of about $56.36 per share, so at $20.64 the stock looks undervalued (173.1% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Privia Health Group scores 73/100 on Intrinsiqq's quality scorecard (a solid business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $56.36 per share for PRVA, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $42.27. At today's $20.64, that puts the stock about 173.1% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Privia Health Group scores 73 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a solid business on these measures. Recent fundamentals include a 1.6% operating margin and a 2.6% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. PRVA currently trades below its estimated intrinsic value and scores 73/100 on quality (solid). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.